Zobrazeno 11 - 20
of 59
pro vyhledávání: '"Ingrid Teige"'
Autor:
Stina Wichert, Gunnar Juliusson, Åsa Johansson, Elisabeth Sonesson, Ingrid Teige, Anna Teige Wickenberg, Björn Frendeus, Magnus Korsgren, Markus Hansson
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0171205 (2017)
BACKGROUND:Smoldering multiple myeloma (SMM) is an indolent disease stage, considered to represent the transition phase from the premalignant MGUS (Monoclonal Gammopathy of Undetermined Significance) state towards symptomatic multiple myeloma (MM). E
Externí odkaz:
https://doaj.org/article/d69c5b902b774938a893144bdf01357b
Autor:
Guido Tricot, Martine Poelman, Magnus Korsgren, Björn Frendeus, Maurizio Zangari, Stina Wichert, Jan Van Droogenbroeck, Ingrid Teige, Annika Sundberg, Yvonne Stenberg, Morten Mau-Sorensen, Elisabeth Sonesson, Morten Salomo, Fritz Offner, Hareth Nahi, Titti Martinsson Niskanen, Ashraf Badros, Peter Gimsing, Markus Hansson
Supplemental table 1. Bone marrow BI-505 concentration and MM-cell ICAM-1 expression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a13375faa4934a754b2d055a8470def8
https://doi.org/10.1158/1078-0432.22461654
https://doi.org/10.1158/1078-0432.22461654
Data from A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Autor:
Guido Tricot, Martine Poelman, Magnus Korsgren, Björn Frendeus, Maurizio Zangari, Stina Wichert, Jan Van Droogenbroeck, Ingrid Teige, Annika Sundberg, Yvonne Stenberg, Morten Mau-Sorensen, Elisabeth Sonesson, Morten Salomo, Fritz Offner, Hareth Nahi, Titti Martinsson Niskanen, Ashraf Badros, Peter Gimsing, Markus Hansson
Purpose: This multicenter, first-in-human study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of BI-505, a human anti-ICAM-1 monoclonal antibody, in advanced relapsed/refractory multiple myeloma patients.Experimental Design:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9060671db8c498c0987a1831cf0d2591
https://doi.org/10.1158/1078-0432.c.6524847
https://doi.org/10.1158/1078-0432.c.6524847
Autor:
Björn Nilsson, Björn Frendéus, Eva Erlandsson, Maroulio Pertesi, Ingrid Teige, Abhishek Niroula, Jenny Mattsson, Ludvig Ekdahl, Fredrik Junghus, Ram Ajore
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-8 (2021)
Nature Communications
Nature Communications
Therapeutic antibodies are transforming the treatment of cancer and autoimmune diseases. Today, a key challenge is finding antibodies against new targets. Phenotypic discovery promises to achieve this by enabling discovery of antibodies with therapeu
Autor:
Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Christelle Remy, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L Cleary, Mimoza Bodén, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Eric Quéméneur, Björn Frendéus
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
BackgroundImmune checkpoint blockade (ICB) is a clinically proven concept to treat cancer. Still, a majority of patients with cancer including those with poorly immune infiltrated ‘cold’ tumors are resistant to currently available ICB therapies.
Autor:
Monika, Semmrich, Jean-Baptiste, Marchand, Laetitia, Fend, Matilda, Rehn, Christelle, Remy, Petra, Holmkvist, Nathalie, Silvestre, Carolin, Svensson, Patricia, Kleinpeter, Jules, Deforges, Fred, Junghus, Kirstie L, Cleary, Mimoza, Bodén, Linda, Mårtensson, Johann, Foloppe, Ingrid, Teige, Eric, Quéméneur, Björn, Frendéus
Publikováno v:
Journal for Immunotherapy of Cancer
Background Immune checkpoint blockade (ICB) is a clinically proven concept to treat cancer. Still, a majority of patients with cancer including those with poorly immune infiltrated ‘cold’ tumors are resistant to currently available ICB therapies.
Autor:
Vivian Changying Jiang, Yang Liu, Alexa Jordan, Angela Leeming, Joseph McIntosh, Shengjian Huang, Rongjia Zhang, Qingsong Cai, Zhihong Chen, Yijing Li, Yuxuan Che, Lei Nie, Ingrid Karlsson, Linda Mårtensson, Mathilda Kovacek, Ingrid Teige, Björn Frendéus, Michael Wang
Publikováno v:
Journal of hematologyoncology. 15(1)
Abstract Inevitable relapses remain as the major therapeutic challenge in patients with mantle cell lymphoma (MCL) despite FDA approval of multiple targeted therapies and immunotherapies. Fc gamma receptors (FcγRs) play important roles in regulating
Autor:
Alexander P. Simpson, Ali Roghanian, Robert J. Oldham, H.T. Claude Chan, Christine A. Penfold, Hyung J. Kim, Tatyana Inzhelevskaya, C. Ian Mockridge, Kerry L. Cox, Yury D. Bogdanov, Sonya James, Alison L. Tutt, Daniel Rycroft, Peter Morley, Lekh N. Dahal, Ingrid Teige, Björn Frendeus, Stephen A. Beers, Mark S. Cragg
Publikováno v:
Cell Reports. 40:111099
Many therapeutic antibodies deplete target cells and elicit immunotherapy by engaging activating Fc gamma receptors (FcγRs) on host effector cells. These antibodies are negatively regulated by the inhibitory FcγRIIB (CD32B). Dogma suggests inhibiti
Autor:
Linda Mårtensson, Robert Oldham, Marie Borggren, Mathilda Kovacek, Therese Blidberg, Ulla-Carin Tornberg, Ingrid Karlsson, Steve Beers, Mark Cragg, Ingrid Teige, Björn Frendeus
Publikováno v:
Cancer Research. 82:3423-3423
Therapeutic antibodies have improved survival of both hematologic and solid cancer patients, inducing long-lasting responses and even cures. Clinically successful antibodies exert antitumor activity by targeting tumor cells directly (e.g. anti-HER2 m
Autor:
Linda Mårtensson, Kirsty Cleary, Petra Holmkvist, Mathilda Kovacek, Carolin Svensson, Monika Semmrich, Therese Blidberg, Mimoza Demiri, Osman Dadas, Marie Borggren, Vici Pitic, Sean H. Lim, Stephen A. Beers, Susanne Gertsson, Kristoffer S. Rohrberg, Ingrid Karlsson, Andres McAllister, Mark S. Cragg, Björn Frendeus, Ingrid Teige
Publikováno v:
Cancer Research. 82:4156-4156
The pleiotropic TNF-α:TNFR axis plays a central role in immune regulation. While the cellular expression of TNFR1 is broad, TNFR2 expression is mainly restricted to immune cells. The therapeutic potential of targeting TNFR2 for cancer treatment has